NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
· prnewswire.com · popularity 16/100 · 0 similar stories today
Read the original at prnewswire.com →
Summary
Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON CAMBRIDGE, Mass., Oct. 29, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a biotechnology company developing...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 17.